Over 10% of people in the United States have some form of eczema and nearly one-fifth experience more than one eczema ...

Seborrheic dermatitis (SD) is non-contagious, chronic (long-term), and recurrent (meaning symptoms come and go) inflammatory disorder. It most commonly affects adults, but a more short-term type ...

Among the key findings, the study highlighted that nearly 1 in 5 adult eczema patients may ... common co- occurring types were: atopic dermatitis and seborrheic dermatitis (25.9%); allergic ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, ...

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE foam, 0.3%, is indicated for the ...

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE foam, 0.3%, is indicated for the ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Later on in the day, confirmation finally came in – Zoryve had been approved as a new, once-daily treatment for mild to moderate atopic dermatitis in adults and children six years of age and ...